Last $54.93 USD
Change Today +0.63 / 1.16%
Volume 911.3K
TEVA On Other Exchanges
Symbol
Exchange
New York
OTC US
Mexico
Frankfurt
As of 11:42 AM 07/22/14 All times are local (Market data is delayed by at least 15 minutes).

Transactions by TEVA PHARMACEUTICAL-SP ADR (TEVA) in the last 6 months

Announced 06/3/14
825.00M for Labrys Biologics, Inc.
Merger/Acquisition

Teva Pharmaceutical Industries Limited (NYSE:TEVA) entered into a definitive agreement to acquire Labrys Biologics, Inc. from venBio LLC, Canaan Partners, InterWest Partners LLC, Sofinnova Ventures, Inc. and other investors for approximately $830 million on June 3, 2014. Under the terms of the agreement, Teva will acquire Labrys for $200 million in upfront payment in cash at closing as well as up to $625 million in contingent payments upon achievement of certain pre-launch ...
Read More


TEVA's price was unchanged after the transaction was announced on 06/3/14.
Investor / Buyer
Teva Pharmaceutical Industries Limited
Creditor / Lender
Canaan Partners
InterWest Partners LLC
Sofinnova Ventures, Inc.
venBio LLC
Legal Advisor
Latham & Watkins LLP
 
Announced 03/18/14
Gamida Cell Ltd.
Merger/Acquisition

A global pharmaceutical company made a non-binding proposal to acquire Gamida Cell Ltd. from a group of sellers on March 7, 2014. The group of sellers include Elbit Medical Technologies Ltd. (TASE:EMTC), Clal Biotechnology Industries (TASE:CBI), Amgen Ventures, Israel Healthcare Ventures, Teva Pharmaceutical Industries Limited, Auriga Partners, Denali Ventures LLC and other shareholders. The proposed consideration for such purchase is expected to include a payment of ...
Read More


TEVA's price was unchanged after the transaction was announced on 03/18/14.
Creditor / Lender
Amgen Ventures
Auriga Partners
Clal Biotechnology Industries Ltd.
Denali Ventures LLC
Elbit Medical Technologies Ltd.
Israel Healthcare Ventures
Teva Pharmaceutical Industries Limited
 
Announced 02/24/14
72.00M for Andromeda Biotech Ltd.
Merger/Acquisition

Teva Pharmaceutical Industries Limited (NYSE:TEVA) signed an agreement to acquire 96% stake in Andromeda Biotech Ltd. from Clal Biotechnology Industries (TASE:CBI) for $72 million on February 24, 2014. The purchase price will be paid in future based on revenue milestones acheived by Andromeda Biotech Ltd.


TEVA's price was unchanged after the transaction was announced on 02/24/14.
Investor / Buyer
Teva Pharmaceutical Industries Limited
Creditor / Lender
Clal Biotechnology Industries Ltd.
 
Announced 02/11/14
7.00M for Teva Pharmaceutical Industries Limited
Merger/Acquisition

Phillip Frost sold 0.02% stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) for $7 million during 2013. Phillip Frost sold 0.17 million shares. Following the sales, Phillip Frost owns 14.42 million shares of Teva.


TEVA's price was unchanged after the transaction was announced on 02/11/14.
 
Announced 02/10/14
Teva Pharmaceutical Industries Limited
Merger/Acquisition

Capital Research and Management Company and Capital Research Global acquired a 5.6% stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) on December 31, 2013. Capital Research & Management Co. beneficially owned 52.57 million Teva shares. Capital Research Global owns 48.43 million Teva shares.


TEVA's price was unchanged after the transaction was announced on 02/10/14.
 
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TEVA:US $54.93 USD +0.63

TEVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $43.04 USD +0.08
AbbVie Inc $54.10 USD +0.10
Amgen Inc $120.72 USD +1.69
Baxter International Inc $76.95 USD +0.84
Eli Lilly & Co $63.92 USD +0.28
View Industry Companies
 

Industry Analysis

TEVA

Industry Average

Valuation TEVA Industry Range
Price/Earnings 33.3x
Price/Sales 2.3x
Price/Book 2.0x
Price/Cash Flow 37.3x
TEV/Sales 1.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TEVA PHARMACEUTICAL-SP ADR, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.